Aptose Biosciences Inc (APTO) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aptose Biosciences Inc   (APTO)


Aptose Biosciences Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Aptose Biosciences Inc's ROI in the first quarter of 2026?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Aptose Biosciences Inc 's return on investment (ROI) in its first quarter of 2026

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 0 1 0 -3 2
Return On Investment (TTM) 8904.36 % -328619.35 % 1426.28 % - 623.5 %
APTO's Overall Ranking # 3971 # 2759 # 3643 # 3316 #
Seq. Investment Change TTM - - - - -
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -28 -25 -19 -21 -21

APTO Company Profile >> Back to APTO Roi Comparisons >> See Annual APTO Return On Investment



Return On Investment APTO's Ranking
Within: No.
Industry # 112
Sector # 721
Overall # 3971

Return On Investment Statistics
High Average Low
-49.11 %
-324.79 %
-3153.51 %
(Sep 30 2020)   (Jun 30 2024)



  News about Aptose Biosciences Inc Return on Investment ROI

Aptoses Ambitious Triplet Therapy A Game Changer for Newly Diagnosed AML Amidst Financial Challenges

November 8, 2024

In an era where innovation meets urgency, Aptose Biosciences Inc. is making notable strides in the treatment landscape for newly diagnosed acute myeloid leukemia (AML). In the recently released third quarter results for 2024, Aptose announced an exciting collaboration with Hanmi Pharmaceutical, embarking on a co-development journey of an innovative triplet therapy. This new treatment combines the promising drug Tuspetinib with Azacitidine and Venetoclax, aiming to reshape the standard care for AML patients.The urgency for effective therapies in the AML landscape cannot be overstated, as new cases of this aggressive leukemia continue to surge globally. With standard treatments often yielding limited outcomes, Aptose’s foray into triplet therapy offers hope that could transform the lives of countless patients diagnosed with this formidable disease.

Aptose Biosciences: Navigating Challenges and Progress in the Healthcare Sector

May 31, 2024



In recent news, Aptose Biosciences Inc, a leading biopharmaceutical company, has announced a registered direct offering priced at-the-market under Nasdaq rules, raising $4.43 million. This development comes amidst a decline in share prices, which plummeted by -30.63% during the second quarter of 2024. Furthermore, the company recorded a significant net loss of $49 million in the twelve-month period ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -221.97%. Despite these challenges, Aptose Biosciences Inc has showcased progress in the healthcare sector, improving its overall ROI ranking.

The registered direct offering marks an important financial move for Aptose Biosciences Inc, aiming to generate capital and fund its ongoing operations. Under Nasdaq rules, this approach allows the company to raise funds by selling shares directly to investors at market prices. However, the announcement coincides with a sharp decline in share prices during the second quarter of 2024, which is a cause for concern among stakeholders.





Financial Statements
Aptose Biosciences Inc's I. Quarter Investments $ 0 Millions APTO's Balance sheet
Aptose Biosciences Inc's I. Quarter Income $ -8 Millions Quarterly APTO's Income Statement
APTO's Income by Division See APTO's Income by Division


APTO Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions -26 -5 -2 39 74
Y / Y Investment Growth - - - -47.89 % -37.76 %
Net Income in Millions -25 -25 -51 -42 -65
Y / Y Net Income Growth - - - - -
Annual Return On Investment - - - -107.95 % -87.9 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
APTO's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for APTO's Competitors
Subscribers only: Roi for Aptose Biosciences Inc's Suppliers
Subscribers only: Return On Investment for APTO's Customers

Other Ratios
APTO's Roa APTO's Inventory Turnover Ratio APTO's Growth Rates APTO's Dividend Statistics
APTO's Profitability Ratios APTO's Asset Turnover Ratio APTO's Dividend Growth
APTO's Roe APTO's Valuation Ratios APTO's Financial Strength Ratios APTO's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Galera Therapeutics Inc   2,637.52 %

Date modified: 2026-06-23T17:39:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.